Drug intelligence / Profile preview

EB6103

Development stage: Preclinical
Lead developer: EmpathBio
Modality: Small Molecules
Administration: Parenteral

Overview

EB6103 is a small molecule glycomacrolide being developed by EmpathBio for the treatment of leukemia and solid tumors. It functions by targeting the F subunit of ATP synthase/hydrolase, an enzyme complex critical for cellular energy production and metabolic regulation. By modulating this target, EB6103 aims to selectively disrupt the bioenergetics of malignant cells, which frequently exhibit metabolic vulnerabilities compared to healthy cells. The program is currently in the IND-enabling phase of development.

Targets

ATP5PF (ATP synthase subunit F6, mitochondrial)

Beyond the preview

Go deeper on EB6103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EB6103.

Explore the full profile